Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.40 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL6936869 | 0.94 | ALDH1A1 (0.48) | ALDH1A1SLC1A2SLC1A1S1PR2S1PR1 | |
| Acetic Acid SCHEMBL28361108 | 0.92 | ALDH1A1 (0.52) | ALDH1A1SLC1A2SLC1A1S1PR2S1PR1 | |
| Acetic Acid SCHEMBL11789825 | 0.92 | ALDH1A1 (0.52) | ALDH1A1SLC1A2SLC1A1S1PR2S1PR1 | |
| Acetic Acid SCHEMBL4073581 | 0.92 | ALDH1A1 (0.52) | ALDH1A1SLC1A2SLC1A1S1PR2S1PR1 | |
| Acetic Acid SCHEMBL28837440 | 0.90 | ALDH1A1 (0.50) | ALDH1A1SLC1A2SLC1A1S1PR2S1PR1 | |
| Acetic Acid SCHEMBL852247 | 0.86 | ALDH1A1 (0.48) | ALDH1A1SLC1A2SLC1A1SLC1A3DPP7 | |
| Acetic Acid SCHEMBL5674651 | 0.86 | ALDH1A1 (0.48) | ALDH1A1SLC1A2SLC1A1SLC1A3DPP7 | |
| SCHEMBL4323430 | 0.86 | — | — | |
| SCHEMBL132040 | 0.86 | — | — | |
| SCHEMBL18271391 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9603954-B2 | Methods for generating radioimmunoconjugates | ACTINIUM PHARMACEUTICALS INC. (US) | 2017-03-28 | — | — | US | claimed |
| US-20120220754-A1 | METHODS FOR GENERATING RADIOIMMUNOCONJUGATES | ACTINIUM PHARMACEUTICALS INC. (US) | 2012-08-30 | — | — | US | claimed |
| EP-2456472-A1 | METHODS FOR GENERATING RADIOIMMUNOCONJUGATES | Actinium Pharmaceuticals Inc. (US) | 2012-05-30 | — | — | EP | claimed |
| WO-2011011592-A1 | METHODS FOR GENERATING RADIOIMMUNOCONJUGATES | ACTINIUM PHARMACEUTICALS INC. (US) | 2011-01-27 | — | — | WO | claimed |
| EP-2155162-A1 | COMPOSITIONS FOR REDUCING, AMELIORATING, TREATING, OR PREVENTING CONDITION OF DRY EYE AND METHODS OF MAKING AND USING SAME | Bausch & Lomb Incorporated (US) | 2010-02-24 | — | — | EP | claimed |
| WO-2008137496-A1 | COMPOSITIONS FOR REDUCING, AMELIORATING, TREATING, OR PREVENTING CONDITION OF DRY EYE AND METHODS OF MAKING AND USING SAME | BAUSCH & LOMB INCORPORATED (US) | 2008-11-13 | — | — | WO | claimed |
| US-20080275000-A1 | COMPOSITIONS FOR REDUCING, AMELIORATING, TREATING, OR PREVENTING CONDITION OF DRY EYE AND METHODS OF MAKING AND USING SAME | SALIX PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | claimed |
| US-20070009435-A1 | Compositions and methods for enhanced delivery to target sites | GENERAL ELECTRIC COMPANY | 2007-01-11 | — | — | US | claimed |
| US-20070009428-A1 | Compounds and methods for enhanced delivery to disease targets | GENERAL ELECTRIC COMPANY | 2007-01-11 | — | — | US | claimed |
| US-20070009427-A1 | Compounds and methods for enhanced delivery to disease targets | GENERAL ELECTRIC COMPANY | 2007-01-11 | — | — | US | claimed |
| US-20060058218-A1 | Solid phase conjugation of complexing agents and targeting moieties | GENERAL ELECTRIC COMPANY (US) | 2006-03-16 | — | — | US | claimed |
| US-6983801-B2 | Well treatment fluid compositions and methods for their use | BJ SERVICES COMPANY (US) | 2006-01-10 | — | — | US | claimed |
| US-20050260131-A1 | Pharmaceuticals for enhanced delivery to disease targets | GENERAL ELECTRIC COMPANY | 2005-11-24 | — | — | US | claimed |
| WO-2005018680-A1 | TARGET-SPECIFIC ACTIVATABLE POLYMERIC IMAGING AGENTS | GENERAL ELECTRIC COMPANY (US) | 2005-03-03 | — | — | WO | claimed |
| US-20050036947-A1 | polyamino acid, wherein at least 90 percent of the amino acid residues are conjugated to signal-generating moieties attached to signal-controlling moieties via bonds that are cleavable by a physiological substance produced by the target; used in detecting and/or diagnosing of diseases; MRI | GENERAL ELECTRIC COMPANY | 2005-02-17 | — | — | US | claimed |
| US-20050016733-A1 | Well treatment fluid compositions and methods for their use | COMBINED SYSTEMS, INC. | 2005-01-27 | — | — | US | claimed |
| WO-2005004992-A2 | MAGNETIC RESONANCE CONTRAST-ENHANCING AGENTS AND METHOD FOR DETECTING AND IMAGING ARTHEROSCLEROTIC PLAQUE | GENERAL ELECTRIC COMPANY (A NEW YORK CORPORATION) (US) | 2005-01-20 | — | — | WO | claimed |
| US-20040265235-A1 | Magnetic resonance contrast-enhancing agents and method for detecting and imaging artherosclerotic plaque | GENERAL ELECTRIC COMPANY | 2004-12-30 | — | — | US | claimed |
| US-20020125012-A1 | Well treatment fluid compositions and methods for their use | BJ SERVICES COMPANY | 2002-09-12 | — | — | US | claimed |
| WO-2002055843-A1 | WELL TREATMENT FLUID COMPOSITIONS AND METHODS FOR THEIR USE | BJ SERVICES COMPANY (US) | 2002-07-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050260131-A1 | Pharmaceuticals for enhanced delivery to disease targets | DNPEP, IAPP, PCSK9 | ALDH1A1 4708/4885SLC1A2 1223/4885SLC1A1 1430/4885 |
| US-20070009428-A1 | Compounds and methods for enhanced delivery to disease targets | SERPINA6, PAICS, FABP1 | ALDH1A1 844/4885SLC1A2 1199/4885SLC1A1 1094/4885 |
| US-20080275000-A1 | COMPOSITIONS FOR REDUCING, AMELIORATING, TREATING, OR PREVENTING CONDITION OF DRY EYE AND METHODS OF MAKING AND USING SAME | PDE6D, PDE6H, CA2 | ALDH1A1 993/4885SLC1A2 1640/4885SLC1A1 1735/4885 |
| US-20070009427-A1 | Compounds and methods for enhanced delivery to disease targets | SELPLG, FABP1, PIGO | ALDH1A1 1025/4885SLC1A2 1103/4885SLC1A1 905/4885 |
| US-20060058218-A1 | Solid phase conjugation of complexing agents and targeting moieties | PCNA, SSU72, RNGTT | ALDH1A1 3999/4885SLC1A2 1529/4885SLC1A1 1126/4885 |
| US-20070009435-A1 | Compositions and methods for enhanced delivery to target sites | PAICS, APOB, ABCG2 | ALDH1A1 3941/4885SLC1A2 2005/4885SLC1A1 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.